DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Spirolactone
Spirolactone
COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone During SARS-Cov-2 Infection
Guidance for the Format and Content of the Protocol of Non-Interventional
Selection of a Mineralocorticoid Receptor Antagonist for Patients with Hypertension Or Heart Failure
Aldactazide® 25
Aldactone® Spironolactone Tablets, USP
Progesterone and Related Progestins: Potential New Health Benefi Ts
SC-26304) (Kidney/Aldosterone Receptors/Tritiated Spirolactone) DIANA MARVER, JOHN STEWART*, JOHN W
ALDACTAZIDE- Spironolactone and Hydrochlorothiazide Tablet, Film Coated
Downloaded from Bioscientifica.Com at 10/01/2021 06:44:53AM Via Free Access
ALDACTONE (Spironolactone)
Spironolactone 25 Mg
Spironolactone
Effects of Aldosterone and Potassium-Sparing Diuretics on Electrical Potential Differences Across the Distal Nephron
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Clinical Protocol IM101566
EACS Guidelines Version 10.0, November 2019
Hazardous Chemical Agents (Anti-Neoplastic, Carcinogens, Reproductive Hazards, Neurotoxic)
Efficacy and Cardiovascular Safety of the New Estrogen-Free Contraceptive
Top View
Spironolactone and Hydrochlorothiazide Tablets
Oral Contraceptions in the Treatment of Hyperandrogenism
Rx Onlyspironolactone and HYDROCHLOROTHIAZIDE TABLETS USP 25 Mg / 25 Mg
The Effects of a Reported Aldosterone Antagonist, Spirolactone, on Salivary
PRILACTONE, INN-Spironolactone
[Product Monograph Template
Commentary Oral Contraceptive Generations
Progestogen Use in the Menopause
Update on Contraceptive Methods
Mineralocorticoid Receptor Antagonists: Achieving Cardiovascular Benefit with Minimized Renal Side Effects? European Heart Journal 34 2426–2428
Pharmacology of Progestogens Kuhl H J
Newer Progestogens
Docking Molecular Analysis of Potential Aldosterone Antagonists
Establishment of Framework for Classification/Categorisation and Labelling of Medicinal Drugs and Driving
Mineralocorticoid Receptor Antagonists: Achieving Cardiovascular Benefit with Minimized Renal Side Effects? European Heart Journal 34 2426–2428